Liu J - Search Results

1

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer.

Liu J, Zhao Y, He D, Jones KM, Tang S, Allison DB, Zhang Y, Chen J, Zhang Q, Wang X, Li C, Wang C, Li L, Liu X. Liu J, et al. Among authors: liu x. Cell Rep Med. 2023 Apr 18;4(4):101015. doi: 10.1016/j.xcrm.2023.101015. Cell Rep Med. 2023. PMID: 37075701 Free PMC article.

2

Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.

Chen X, Liu J, Cheng L, Li C, Zhang Z, Bai Y, Wang R, Han T, Huang C, Kong Y, Feng F, Liu X. Chen X, et al. Among authors: liu j, liu x. Prostate. 2020 Feb;80(3):256-266. doi: 10.1002/pros.23939. Epub 2019 Dec 19. Prostate. 2020. PMID: 31856338

3

Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.

Li C, Lanman NA, Kong Y, He D, Mao F, Farah E, Zhang Y, Liu J, Wang C, Wei Q, Liu X. Li C, et al. Among authors: liu j, liu x. J Biol Chem. 2020 Apr 17;295(16):5470-5483. doi: 10.1074/jbc.RA119.011385. Epub 2020 Mar 17. J Biol Chem. 2020. PMID: 32184358 Free PMC article.

4

p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.

Liu J, He D, Cheng L, Huang C, Zhang Y, Rao X, Kong Y, Li C, Zhang Z, Liu J, Jones K, Napier D, Lee EY, Wang C, Liu X. Liu J, et al. Among authors: liu x. Oncogene. 2020 May;39(19):3939-3951. doi: 10.1038/s41388-020-1270-z. Epub 2020 Mar 23. Oncogene. 2020. PMID: 32203167 Free PMC article.

5

Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.

Kong Y, Zhang Y, Mao F, Zhang Z, Li Z, Wang R, Liu J, Liu X. Kong Y, et al. Among authors: liu j, liu x. Mol Cancer Ther. 2020 Dec;19(12):2490-2501. doi: 10.1158/1535-7163.MCT-19-0874. Epub 2020 Oct 6. Mol Cancer Ther. 2020. PMID: 33024029 Free PMC article.

6

[No title available]

[No authors listed] [No authors listed] PMID: 33509588

7

Co-Targeting Plk1 and DNMT3a in Advanced Prostate Cancer.

Zhang Z, Cheng L, Zhang Q, Kong Y, He D, Li K, Rea M, Wang J, Wang R, Liu J, Li Z, Yuan C, Liu E, Fondufe-Mittendorf YN, Li L, Han T, Wang C, Liu X. Zhang Z, et al. Among authors: liu j, liu x, liu e. Adv Sci (Weinh). 2021 Jul;8(13):e2101458. doi: 10.1002/advs.202101458. Epub 2021 May 29. Adv Sci (Weinh). 2021. PMID: 34051063 Free PMC article.

8

Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.

Mao F, Kong Y, Liu J, Rao X, Li C, Donahue K, Zhang Y, Jones K, Zhang Q, Xu W, Liu X. Mao F, et al. Among authors: liu j, liu x. Prostate. 2022 Jun;82(8):917-932. doi: 10.1002/pros.24336. Epub 2022 Mar 24. Prostate. 2022. PMID: 35322879 Free PMC article.

9

Epigenetics in prostate cancer treatment.

Jones K, Zhang Y, Kong Y, Farah E, Wang R, Li C, Wang X, Zhang Z, Wang J, Mao F, Liu X, Liu J. Jones K, et al. Among authors: liu j, liu x. J Transl Genet Genom. 2021;5:341-356. doi: 10.20517/jtgg.2021.19. Epub 2021 Aug 27. J Transl Genet Genom. 2021. PMID: 35372800 Free PMC article.

10

Co-Targeting Plk1 and DNMT3a in Advanced Prostate Cancer.

Zhang Z, Cheng L, Zhang Q, Kong Y, He D, Li K, Rea M, Wang J, Wang R, Liu J, Li Z, Yuan C, Liu E, Fondufe-Mittendorf YN, Li L, Han T, Wang C, Liu X. Zhang Z, et al. Among authors: liu j, liu x, liu e. Adv Sci (Weinh). 2022 Jul;9(20):e2202572. doi: 10.1002/advs.202202572. Adv Sci (Weinh). 2022. PMID: 35837804 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

135,264 results

Search Page